Bio-Rad (BIO) delivers robust performance, primarily in North America, China and the Asia-Pacific region.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, and Christine...
Bio-Rad (BIO) Q1 results reflect impressive segmental sales and solid performance across all geographies.
Bio-Rad Labs-A (NYSE:BIO) traded in a range yesterday that spanned from a low of $283.51 to a high of $293.43. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of...
Here are the top 5 stocks in the Life Sciences Tools & Services industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were...
An important component of the broader Medical sector, the Medical Product space consistently grabs attention owing to a string of upsides.
Baxter (BAX) gains ground on strategic buyouts and a raised guidance for 2018.
Integra LifeSciences' (IART) revenue growth was primarily driven by high organic revenues, successful progress with Codman integration and progress with the channel expansion strategy.
LabCorp's (LH) Diagnostics business was solid on the back of increasing acquisitions, organic volume expansion and a favorable foreign exchange scenario.
Thermo Fisher's (TMO) performance in Q1 benefits from a series of product launches alongside a major progress in precision medicine initiatives.
Illumina's (ILMN) collaboration with Bristol-Myers Squibb and Loxo Oncology are likely to yield results in the near term.
Edwards Lifesciences (EW) gains from THVT strength on continued therapy adoption across all geographies in Q1.
Boston Scientific (BSX) registers steady growth across all business lines and geographies in Q1.
Integer Holdings' (ITGR) unswerving focus on customer relationship, cost reduction and burgeoning financial performance are key catalysts.
Edwards Lifesciences (EW) is expected to gain from strength in THVT on continued therapy adoption across all geographies in Q1.
Stryker (SYK) gains from stellar performance of the flagship Mako platform; guidance solid.
Chemed (CHE) rides on strong contributions from the Roto-Rooter and VITAS businesses in Q1.
Quest Diagnostics' (DGX) year-over-year revenue improvement in Q1 came on the back of successful execution of its two-point strategy of accelerating growth and driving operational excellence.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the first quarter 2018 on Tuesday,...
Abbott (ABT) continues to gain from a strong and consistent EPD as well as a robust Medical Devices performance.